A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer

Clinical Cancer Research

Volumn 7, Issue 12, 2001, Pages 3920-3927

  Chi, Kim N ^a,b   Gleave, Martin E ^a,b   Klasa, Richard ^a   Murray, Nevin ^a   Bryce, Cicely ^a   Lopes de Menezes, Daniel E ^a   D’Aloisio, Susan ^a   Tolcher, Anthony W ^c  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c CTRC Institute for Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CREATININE; MESSENGER RNA; MITOXANTRONE; OBLIMERSEN; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTHRALGIA; ARTICLE; BOLUS INJECTION; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG TOLERABILITY; FATIGUE; FEVER; GENE THERAPY; HUMAN; LYMPHOCYTOPENIA; MALE; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MIDDLE AGED; MITOXANTRONE; NEOPLASM METASTASIS; PATIENT SELECTION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; THIONUCLEOTIDES;

EID: 0035678781     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. An adjustment to the 1997 estimate for new prostate cancer cases
2. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
3. Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?
4. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points
5. Hydrocortisone with and without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 study
6. Analysis and structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma
7. Bcl-2 and the regulation of programmed cell death
8. bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line
9. bcl-2 overexpression delays radiation induced apoptosis without affecting the clonogenic survival of human prostate cancer cells
10. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen-independent prostate cancer
11. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers
12. Expression of the protooncogene Bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer
13. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo
14. Prognostic significance of Bcl-2 in clinically localized prostate cancer
15. BCL-2, and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy
16. Therapeutic application of oligonucleotides
17. Antisense Bcl-2 oligodeoxynucleotides inhibit expression to androgen-independence after castration in the Shionogi tumor model
18. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model
19. Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense BCL-xL and antisense Bcl-2 oligonucleotides plus Taxol after castration in the shionogi tumor model
20. Synergistic chemosensitization and inhibition of progression to androgen-independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model
21. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligonucleotides
22. Phase I clinical and pharmacokinetic study of Bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin’s lymphoma
23. Reporting results of cancer treatment
24. Quantitative fluorescence cytometric analysis of Bcl-2 levels in tumor cells exhibiting a wide range of inherent Bcl-2 protein expression: Correlation with Western blot analysis
25. Determination of antisense phosphorothioate oligonucleotides and catabolites in biological fluids and tissue extracts using anion-exchange high-performance liquid chromatography and capillary gel electrophoresis
26. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice
27. Chemosensitization of malignant melanoma by BCL-2 antisense therapy
28. A Phase I trial of G3139 (Genta, Inc.), a BCL2 antisense drug, by continuous infusion (CI) as a single agent and with weekly Taxol (T)
29. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair
30. Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302)
31. Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies
32. Phase I/pharmacokinetic/pharmacodynamic trial of Raf-1 antisense ODN (ISIS 5132, CGP 69846A)
33. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) trial of bcl-2 antisense (Genasense) and docetaxel (D) in hormone refractory prostate cancer
34. Molecular and pharmacokinetic properties associated with the therapeutics of Bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin
35. Pharmacokinetic and pharmacodynamic studies with mitoxantrone in the treatment of patients with nasopharyngeal carcinoma
36. Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression
37. A Phase II trial of docetaxel in patients with hormone refractory prostate cancer: Long term results
38. Bcl-2 is the guardian of microtubule integrity